Talima Therapeutics
Drug delivery company developing customized systems that optimize the local therapeutic performance
About Talima Therapeutics
Talima Therapeutics was a biopharmaceutical firm established in 2004 and officially founded in 2005, focusing on site-specific drug delivery systems. The company, which is now closed, aimed to develop products that localized therapeutic effects and minimized systemic side effects, thereby addressing unmet needs in the market. Initially led by founding CEO David Henkel-Wallace, Talima's core technology was a proprietary micro-implant system (TMI) designed for the localized application of small-molecule drugs. The company's initial strategic focus was on the dermatology market, where systemic drugs often have adverse effects that limit their use. Conditions like onychomycosis (nail fungus), psoriasis, and severe acne were identified as key target areas where a localized treatment could offer a significant advantage over existing oral medications. The primary product in Talima's pipeline was a micro-implant for treating onychomycosis. This product, which entered Phase I/II clinical trials, was designed to deliver a small-molecule drug directly to the site of the fungal nail infection. This approach intended to provide a safer alternative to widely used oral drugs like terbinafine, which carried risks of systemic side effects. In January 2008, Martin Babler, a former executive at Genentech and Eli Lilly with a background in pharmaceutical science, was appointed President and CEO to guide the company from the proof-of-concept stage toward commercialization. From a financial perspective, Talima Therapeutics secured a significant Series B funding round of $19 million in May 2007. This oversubscribed round was led by US Venture Partners and Latterell Venture Partners, with participation from existing investors De Novo Ventures and Palo Alto Healthcare. The capital was intended to advance the company's product through Phase II clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2004
- Headquarters
- San Carlos, United States
- Employees
- 3
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, medical implants, Dermatology, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2007 | $19M | $76M | U.S. Venture Partners · Latterell Venture Partners | — |
| SERIES A✓Equity / VC | May 2005 | $1.6M | $6.4M | Palo Alto Investors · DeNovo Ventures | — |
Growth signals
Latest recorded traffic for Talima Therapeutics is 0 monthly website visits, down 100% over the last three months. Talima Therapeutics's team grew 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talima Therapeutics in the San Carlos ecosystem
The Talima Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- PIPalo Alto Investors
- DVDeNovo Ventures
U.S. Venture Partners
Latterell Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Talima Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Talima Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









